Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1 3Phase 4 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 6Carcinoma, Hepatocellular 3Multiple Myeloma 2Urothelial Cancer 1Urologic Neoplasms 1Stomach Neoplasms 1Recurrence 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Kidney Neoplasms 1Kidney Diseases 1Gliosarcoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 6aldesleukin 6Cyclophosphamide 6fludarabine phosphate 5fludarabine 5Nivolumab 4durvalumab 3Sorafenib 3Radiotherapy 3Filgrastim 3Everolimus 3Axitinib 3Temozolomide 2Peripheral Blood Stem Cell Transplantation 2Isotretinoin 2Ipilimumab 2Interleukin-2 2Interferon-alpha 2Fluorouracil 2Dexamethasone 2Cyclosporine 2Bevacizumab 2vorolanib 1tremelimumab 1tocilizumab 1talazoparib 1spartalizumab 1sargramostim 1poly ICLC 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Kidney Neoplasms × cabozantinib × Clear all
NCT04300140 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Aravive, Inc.

Phase 1/2 Terminated
72 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡